News | June 12, 2008

AMIC Developing Proprietary Brachytherapy Treatment

June 13, 2008 - Advanced Medical Isotope Corp. (AMIC), a company engaged in the production and distribution of medical isotopes, has entered into an agreement to further develop a proprietary brachytherapy treatment with Battelle, which operates the Pacific Northwest National Laboratory (PNNL), and the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah.

AMIC proposes development of a proprietary concept for controlled delivery of yttrium-90 (Y-90) microspheres embedded in resorbable seed-shape materials for tissue directed, high-dose intra-tumoral therapy. Use of Y-90 will help to minimize the radiation dose to nearby normal tissues compared to X-rays from standard seeds. This technology is designed to improve the treatment of confined or non-resectable tumors and is based on a fast-dissolving polymer-matrix chemistry.

Researchers believe this method may provide a significantly lower-cost alternative to existing metallic seeds as well as having the strong possibility of delivering a greater "biological effective" radiation dose to tumors compared to standard industry seeds, said the company.

For more information: